Merck lifted by soaring sales of go-to lung cancer drug
Sales of Keytruda grew 62.5% in the third quarter with its HPV vaccine Gardasil growing 26%
29 October 2019 - 18:41
Bengaluru — On Tuesday, Merck said it expected drug Keytruda to continue its market dominance as an initial treatment for advanced lung cancer as sales of the drug topped $3bn in a quarter for the first time, beating Wall Street estimates.
Merck shares rose more than 2% to $84 in early trading...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.